Lp(a) shows a transient, non-linear increase during the acute phase of ACS associated with inflammatory response, and early post-ACS Lp(a) measurements may not reflect steady-state levels and should be interpreted cautiously.
Abstract
Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease. Because circulating Lp(a) levels are largely genetically determined by the LPA gene, a single lifetime measurement has traditionally been considered sufficient. However, emerging evidence suggests that Lp(a) may fluctuate during the acute phase of acute coronary syndrome (ACS), with a possible peak around two weeks after onset. We aimed to identify clinical determinants of acute-phase Lp(a) changes and characterize its temporal pattern following ACS.
This single-center retrospective study included consecutive ACS patients undergoing percutaneous coronary intervention between January 2023 and January 2026. All received intensive statin therapy and had at least two Lp(a) measurements: at admission and within 30 days. Baseline Lp(a) was defined as the value within 72 hours of admission. ΔLp(a) was calculated as follow-up minus baseline Lp(a).Correlations between ΔLp(a) within 14 days and peak creatine kinase-MB (CK-MB), peak C-reactive protein (CRP), peak aspartate aminotransferase (AST), estimated glomerular filtration rate (eGFR), and baseline Lp(a) were assessed. Multivariable linear regression identified independent determinants. Linear and quadratic regression models were applied to evaluate the overall time-course pattern.
Eighty-four patients were analyzed (mean age 69.4 years; 21.4% female). Baseline Lp(a) was 20.8 ± 19.0 mg/dL. Mean ΔLp(a) was 13.3 ± 14.1 mg/dL, with a maximum increase of 72 mg/dL at 12 days.ΔLp(a) within 14 days correlated with baseline Lp(a) (r = 0.42, p < 0.001) and CRP (r = 0.27, p = 0.016), but not with CK-MB or AST. In multivariable analysis adjusting for age, sex, timing, CRP, and baseline Lp(a), CRP (β = 0.64, p = 0.001) and baseline Lp(a) (β = 0.33, p < 0.001) remained independently associated with ΔLp(a). Quadratic regression demonstrated a significant non-linear trajectory (p for non-linearity = 0.012).
Lp(a) shows a transient, non-linear increase during the acute phase of ACS associated with inflammatory response. Early post-ACS Lp(a) measurements may not reflect steady-state levels and should be interpreted cautiously.Lp(a) Changes in the Acute Phase of ACSCorrelation of baseline Lp(a) and CRP
Lipoprotein(a) [Lp(a)] is a causal, largely genetically determined risk factor for atherosclerotic cardiovascular disease and residual risk after LDL-cholesterol lowering. Contrary to the traditional assumption of lifelong stability, several recent studies suggest that Lp(a) may rise after acute myocardial infarc...
K. Mahajan, J. B. Sharma, S. Himral et al.· European Heart Journal· 0 citations
Lipoprotein(a) [Lp(a)] is a well-established, genetically determined risk factor for atherosclerotic cardiovascular disease. Contemporary consensus guidelines from the ESC and ACC/AHA recommend at least one lifetime Lp(a) measurement; however, interpretation of Lp(a) in the setting of acute ST-elevation myocardia...
J. Yoon, N. Atefi, F. Hosseini et al.· European Heart Journal· 0 citations
Background and Aims. Lipoprotein (a) [Lp(a)] is a well-established, independent, atherosclerotic cardiovascular risk factor. Several studies have demonstrated its prognostic value, alongside traditional risk factors, in patients with acute myocardial infarction (AMI), contributing to improved risk stratification and th...
Giulia Barbieri· Bleeding Thrombosis and Vasc...· 0 citations
The concept of lifelong Lp(a) stability is challenged and consideration of repeated Lp(a) measurements in selected patients with established cardiovascular disease is supported.
C. Zhang, G. Huré, A. Champetier et al.· European Heart Journal· 0 citations
Lipoprotein(a) [Lp(a)] is a genetically determined lipid particle associated with residual cardiovascular risk and its measurement is recommended at least once in adulthood. Although recent evidence suggests that Lp(a) should ideally be measured outside acute inflammatory states, it is still frequently assessed d...
D. Monteiro, S. Martinho, A. R. Ramalho et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.